Alzey Danışmanlık ve Ticaret Ltd. Şti. · İstanbul
Most distributors put your product on a shelf. We also build the demand that pulls it off.
We hold the licence, run the operation and grow the clinic network that sells your product across Türkiye, the Caucasus and Central Asia, where the pathway matters as much as the product.
Such an agreement covers three things: importing the product, warehousing it and delivering it when orders come in. Before a device sells in this region, someone also has to hold the licence, train the physicians, build the demand and manage the receivables; a shelf-only agreement leaves most of that on your side.
We close that gap under one agreement, and that changes the incentive structure: if the product doesn’t move, we carry that outcome too, so we don’t step back from the process.
We run the clinic network on the B2B side and patient demand on the B2C side; both sit inside the same operation, so all three parties gain from the same transaction.
Sells into a channel that holds the licence, carries the stock and answers as one counterparty.
Finds the patients for the device without having to build the demand on its own.
Reaches treatment at the authorised centre that delivers it.
The step-by-step version, from licence to collections, sits on the medical operation page.
We open the pathway.
Registration files run in our name, from the TİTCK licence and ÜTS record in Türkiye to the active markets in Kazakhstan, Uzbekistan, Georgia and Azerbaijan. You supply the technical documentation; the filing, the follow-up and the outcome sit with us.
We open the dossier in our own name and defend it with our own team.
We run it.
Import, customs, stock, field, receivables. The credit risk stays with us.
We take the product from EXW, clear it through customs and hold buffer stock in our own warehouse, so an authorised centre isn’t left waiting on a shipment. You deal with one counterparty, and collections in the field are our problem.
If the product isn’t moving, that’s our problem first.
Where the demand gets built.
We lower the clinic’s patient-acquisition cost through our own demand channel, clinic-level digital marketing and conversion optimisation, and we model the ROI on the clinic’s own numbers.
The patient-facing surfaces, the ad accounts and the CRM are run in-house by our own team. The infrastructure is built; the organic demand engine is still ramping up.
We don’t wait for the market to form; we take that on too.
We don’t publish client names; every line below carries a date and a document behind it.
What “100+ centres” counts: clinics, hospitals, obesity centres, medical-travel agencies and physician practices.
Regulatory status may change; consult official TİTCK and FDA records for the current position.
We don’t sell market-entry reports. If you want a deck, hire a consultancy.
Statuses rest on contracted records; commercial terms are never published on this site.
Ventures: the same operating discipline, applied to F&B brands. For brand partners and investors.
Ventures →A first conversation covers your regulatory position, the commercial model and a realistic timeline, and if we’re not the right partner for your product, you’ll hear that in the same meeting.
